CN114478575A - Barosavirenz crystal form D and preparation method thereof - Google Patents
Barosavirenz crystal form D and preparation method thereof Download PDFInfo
- Publication number
- CN114478575A CN114478575A CN202011262612.XA CN202011262612A CN114478575A CN 114478575 A CN114478575 A CN 114478575A CN 202011262612 A CN202011262612 A CN 202011262612A CN 114478575 A CN114478575 A CN 114478575A
- Authority
- CN
- China
- Prior art keywords
- degrees
- crystal form
- crystal
- baroxavir
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
The invention discloses a crystalline form D of Barosavirenz and a preparation method thereof, wherein the crystalline form D of Barosavirenz is an anhydrous solvate-free crystalline form of Barosavirenz, and has characteristic diffraction peaks at diffraction angles of 4.5 degrees, 8.8 degrees, 10.8 degrees, 13.2 degrees, 14.3 degrees, 14.8 degrees and 16.2 degrees under X-ray powder diffraction, and the test error is +/-0.2 degrees. The research results of the invention show that: the crystal habit of the crystal form D of the Baroswarriol ester is a slender needle-shaped crystal, the solvent is easy to remove by vacuum drying, and crystal particles with the purity of 99.5 percent, impurity residues and solvent limit which meet the quality standard of raw material medicines and have good stability, dispersibility, fluidity and compressibility can be obtained after drying, so that the crystal form D of the Baroswarriol ester is very suitable for being used as a production raw material of tablets; in addition, the crystal form D of the baroxavir disoproxil has solubility superior to that of the existing crystal form in the pH environment simulating gastric and intestinal juice, and is very favorable for absorption and utilization of oral preparations.
Description
Technical Field
The invention relates to a crystal form D of baroxavir disoproxil and a preparation method thereof, belonging to the technical field of pharmaceutical chemistry.
Background
Baroxavir disoproxil (Baloxavir Marboxil) is a new anti-influenza drug developed by Shionogi corporation, Japan, under the trade name Xofluza. Xofluza is an innovative Cap-dependent endonuclease inhibitor, is also a few oral drugs capable of inhibiting the proliferation of influenza viruses in the world, can inhibit the CAP structure at the 5' end of host mRNA obtained from host cells aiming at the key link of the replication of the influenza viruses so as to inhibit the transcription of the self mRNA of the influenza viruses, is approved by Japan in 2 months of 2018 for treating the influenza A and B of adults and paediatric patients, and is approved by FDA in 10 months of 2018 for being marketed for treating the acute influenza patients without complications of 12 years old and over 48 hours.
The baroxavir disoproxil is a prodrug which enters into the body to be hydrolyzed into an active substance baroxavir, and the chemical structural formula of the baroxavir disoproxil is as follows:
according to the reports of the prior literature, the baroxavir ester is a polymorphic compound, such as: patent WO2018030463 discloses three crystal forms of Form I, Form II and Form III of baroxavir ester, wherein the Form I crystal Form is prepared in a mixed solution of dimethyl sulfoxide and water (detailed in example 10), the Form II crystal Form is obtained by dissolving acetonitrile (50mL) and water (5mL) in a mixed solution, then supplementing 95mL of water for crystallization (detailed in example 21), the Form III crystal Form is obtained by heating and dissolving 40 times of methyl acetate, and performing concentration and cooling crystallization under reduced pressure (detailed in example 22); in addition, patent CN201911140898.1 discloses Form A and Form B crystal forms of Baroswarriol ester, wherein the Form A crystal Form is obtained by dissolving a good solvent (such as dimethyl sulfoxide, dimethylformamide, butyl formate and acetone) at normal temperature, then dripping a poor solvent (such as ethanol, water, cyclohexane and isopropyl ether) at normal temperature for crystallization (see examples 1-4 in detail), and the Form B crystal Form is obtained by dissolving acetonitrile at first and then placing at room temperature to completely volatilize the acetonitrile; from the above prior research results, it can be seen that crystalline forms of baroxavir acetate are very sensitive to solvents.
The inventor of this patent also found in experiments that: the Form II crystal Form and the Form III crystal Form are unstable and can be easily converted into the Form I crystal Form in the crystallization process; in addition, although the Form a and Form B crystal forms of the barroxavir ester disclosed in patent CN201911140898.1 have good stability under high temperature, high humidity and illumination conditions, we find that the Form a crystal Form is the Form I crystal Form disclosed in patent WO2018030463, and thermogravimetric analysis of Form B shows that the Form B has a weight loss of about 0.5%, and is an anhydride according to the introduction of the patent, so that partial weight loss indicates that the Form B is a mixed crystal Form mixed with a solvate. And since Form B is obtained by volatilization crystallization from an acetonitrile system, acetonitrile belongs to a second class of solvent specified by ICH, the limit is lower, and on the other hand, mixed crystals can influence the dissolution of the preparation, Form B in the Form of acetonitrile solvate cannot be used as a medicament, and the Form B crystal Form needs to be prepared by natural volatilization of acetonitrile solution at room temperature for 3-4 days, so that the problem that the solvent residue is not qualified due to mixed crystals is more likely to occur because industrial production cannot be realized definitely, a large amount of acetonitrile solvent is volatilized into air, and the environmental protection is not facilitated. For the reasons, the raw material used for the oral preparation at present is a Form I crystal Form (the Form I crystal Form is the same crystal Form as the Form A crystal Form), but the existing Form I crystal Form is flaky, and flaky crystals are easy to wrap a solvent and agglomerate in the process of drying materials, so that the dried materials are hard, the solvent residue is easy to exceed the standard, the solvent limit can be reached by long time of drying, the drying time is too long, and the degraded impurities are easy to exceed the standard; in addition, after the materials are agglomerated, the product has poor fluidity, and can meet the requirement of compressible granularity only by physical grinding, thereby causing great trouble to the production of oral medicinal preparations. Therefore, the development of a new baclovir disoproxil crystal form which is superior to the existing crystal form in the aspects of stability, solubility, fluidity and the like is urgently needed in the field so as to meet the industrial production requirement of the oral baclovir disoproxil preparation.
Disclosure of Invention
In view of the above problems and needs in the prior art, the present invention aims to provide a crystalline form D of baclovir disoproxil, which is superior to the existing crystalline form in terms of stability, solubility, fluidity, etc., so as to meet the industrial production requirements of oral baclovir disoproxil.
In order to achieve the purpose, the invention adopts the following technical scheme:
the crystal form D of the barroxavir ester is an anhydrous solvate-free crystal form of the barroxavir ester, and has characteristic diffraction peaks at diffraction angles 2 theta of 4.5 degrees, 8.8 degrees, 10.8 degrees, 13.2 degrees, 14.3 degrees, 14.8 degrees and 16.2 degrees under X-ray powder diffraction, and the test error is +/-0.2 degrees.
Furthermore, the crystalline form D of baroxavir pivoxil of the present invention has characteristic diffraction peaks at diffraction angles 2 θ of 4.5 °, 8.8 °, 9.8 °, 10.8 °, 11.7 °, 13.2 °, 14.3 °, 14.8 °, 15.8 °, 16.2 °, 16.5 °, 17.3 °, 17.5 °, 17.8 °, 18.8 °, 20.2 °, 21.6 °, 21.9 °, 22.3 °, 24.2 °, 24.4 °, 26.5 °, 28.0 °, 28.3 °, 29.7 ° and 31.5 ° under X-ray powder diffraction, and the test error is ± 0.2 °.
Furthermore, the X-ray powder diffraction pattern of the crystalline form D of baroxavir disoproxil of the present invention is substantially consistent with that of fig. 4.
Furthermore, the DSC spectrogram of the crystal form D of the baroxavir disoproxil has an endothermic peak at 235 ℃.
Furthermore, a DSC spectrum of crystalline form D of baroxavir disoproxil of the present invention is substantially identical to that of fig. 5.
Furthermore, a thermogravimetric analysis spectrogram of the crystalline form D of baroxavir ester disclosed by the invention is basically consistent with that in fig. 6.
A method for preparing the crystal form D of the baroxavir disoproxil comprises the following steps:
a) dissolving a baroxavir base material in a mixed solvent formed by dichloromethane and an ester solvent according to a volume ratio of 1.0 (0.5-2.5) at a dissolving temperature of 20-50 ℃ to obtain a clear solution;
b) then, dropwise adding n-heptane into the system, and stirring to crystallize;
c) filtering and collecting precipitated crystals;
d) and c) drying the crystal obtained in the step c) for 6-15 hours at 50-100 ℃ in vacuum to obtain the crystal form D of the baroxavir disoproxil.
In the step a), the dissolving temperature is preferably 20-40 ℃, and is most preferably 25-35 ℃.
In step a), the form of the baroxavir ester raw material is not limited, and can be amorphous or any known crystal form or a mixture thereof.
In the step a), the mass-to-volume ratio of the baroxavir ester raw material to the mixed solvent is 1 g (8-15) ml, preferably 1 g (8-12) ml, and most preferably 1 g (10) ml.
In the step a), the volume ratio of the dichloromethane to the ester solvent in the mixed solvent is preferably 1.0 (0.8-1.2), and is most preferably 1.0: 1.0.
In the step a), the ester solvent is at least one selected from methyl benzoate, ethyl benzoate, methyl formate, ethyl formate, isopropyl formate, butyl formate and butyl acetate, and most preferably any one selected from methyl benzoate, methyl formate and ethyl formate.
In the step b), the ratio of the volume of n-heptane used to the volume of the mixed solvent used in the step a) is (1-1.2): 1, and is preferably 1: 1.
In the step d), the vacuum drying condition is preferably drying at 70-90 ℃ for 6-10 hours, and is preferably drying at 60-80 ℃ for 6-8 hours.
Compared with the prior art, the invention has the following remarkable beneficial effects:
the research results of the invention show that: the crystal form D of the baroxavir ester is an anhydrous solvent-free crystal form, the crystal habit of the crystal form is a slender needle-shaped crystal, a solvent is easy to remove through vacuum drying, and crystal particles with purity up to 99.5%, impurity residues and solvent limitation which meet the quality standard of raw material medicines and have good stability, dispersibility, fluidity and compressibility can be obtained after drying, so that the baroxavir ester crystal form D is very suitable for being used as a production raw material of tablets; in addition, the crystal form D of the barroxavir ester has better solubility than the existing crystal form in the pH environment simulating gastric and intestinal juice, and is very favorable for the absorption and utilization of oral preparations; in conclusion, compared with the existing known crystal form, the crystal form D of the baroxavir disoproxil has various excellent performances more suitable for oral preparations, and generates remarkable progress and unexpected technical effect compared with the prior art.
Drawings
Figure 1 is an X-ray powder diffraction pattern (XRPD) of form C described in example 1;
FIG. 2 is a Differential Scanning Calorimetry (DSC) spectrum of form C described in example 1;
figure 3 is thermogravimetric analysis data (TGA) of form C described in example 1;
figure 4 is an X-ray powder diffraction pattern (XRPD) of form D described in example 1;
FIG. 5 is a Differential Scanning Calorimetry (DSC) spectrum of form D described in example 1;
figure 6 is thermogravimetric analysis data (TGA) of form D described in example 1;
FIG. 7 is an X-ray powder diffraction pattern (XRPD) of known form I;
figure 8 is an XRPD comparison spectrum of a stability experiment of form D described in example 4;
fig. 9 is a photograph of crystal habit of form D described herein;
fig. 10 is a photograph of a crystal habit of a known form I.
Detailed Description
In the following examples, unless otherwise indicated, the test procedures are generally carried out under conventional conditions or conditions recommended by the manufacturer, and the starting materials and reagents indicated are commercially available.
The parameters of X-ray powder diffraction are as follows (XRPD):
x-ray powder diffraction instrument: brucker D8 advance X-ray powder diffractometer;
x-ray reflectance parameters: copper target
Scanning at room temperature:
voltage: 40 kilovolts (kv);
current: 40 milliamperes (mA);
scanning mode: continuously;
scanning range: 2.0-35.0 ℃;
step length: 0.020 °;
the measuring time of each step is 0.1 second/step;
differential Scanning Calorimetry (DSC) analysis method parameters were as follows:
differential Scanning Calorimetry (DSC) instrument: TA Q2000 type;
temperature range: room temperature to 250 ℃;
scanning speed: 10 ℃/minute;
protective gas: nitrogen, 50 ml/min;
thermogravimetric analysis (TGA) parameters were as follows:
thermogravimetric analysis (TGA) instrument: TGA55 form;
temperature range: room temperature to 300 ℃;
scanning speed: 10 ℃/minute;
protective gas: nitrogen, 60 ml/min.
Example 1
Dissolving 10.0g of bacloxavir ester in a mixed solvent of 50mL of dichloromethane and 50mL of methyl benzoate at room temperature, then dropwise adding 100mL of n-heptane, stirring for crystallization for 1 hour, filtering, leaching a filter cake with n-heptane, and obtaining a crystal, namely the crystal form C, wherein an XRPD spectrum of the crystal is shown in figure 1 and can be seen from figure 1: the 2 theta of the X-ray powder diffraction pattern of the crystal form C has characteristic peaks at 4.0 +/-0.2 degrees, 8.0 +/-0.2 degrees, 11.1 +/-0.2 degrees, 11.4 +/-0.2 degrees, 12.0 +/-0.2 degrees, 13.2 +/-0.2 degrees, 13.6 +/-0.2 degrees, 14.1 +/-0.2 degrees, 14.3 +/-0.2 degrees, 16.1 +/-0.2 degrees, 16.3 +/-0.2 degrees, 17.9 +/-0.2 degrees, 20.2 +/-0.2 degrees, 20.8 +/-0.2 degrees, 23.9 +/-0.2 degrees, 24.3 +/-0.2 degrees, 24.5 +/-0.2 degrees, 25.6 +/-0.2 degrees, 28.5 +/-0.2 degrees and 32.6 +/-0.2 degrees.
Fig. 2 is a differential scanning calorimetry thermogram of said form C, as seen in fig. 2: the crystal form C has endothermic peaks at 90-100 ℃ and 235 ℃.
Fig. 3 is a thermogravimetric analysis spectrum of the form C, as can be seen from fig. 3: the weight loss of the crystal form C is 8.0-11.0% at 90-100 ℃, which indicates that the crystal form C is a solvate of methyl benzoate of the Baroswarriol, wherein the content of the methyl benzoate is 8.0-11.0%.
The resulting form C was dried in a vacuum oven at 80 ℃ for 6 hours to give 9.2g of a solid with an XRPD pattern as shown in figure 4, i.e.: characteristic diffraction peaks are obtained at diffraction angles 2 theta of 4.5 degrees, 8.8 degrees, 9.8 degrees, 10.8 degrees, 11.7 degrees, 13.2 degrees, 14.3 degrees, 14.8 degrees, 15.8 degrees, 16.2 degrees, 16.5 degrees, 17.3 degrees, 17.5 degrees, 17.8 degrees, 18.8 degrees, 20.2 degrees, 21.6 degrees, 21.9 degrees, 22.3 degrees, 24.2 degrees, 24.4 degrees, 26.5 degrees, 28.0 degrees, 28.3 degrees, 29.7 degrees and 31.5 degrees, the test error is +/-0.2 degrees, and the crystal form obtained after drying is marked as a crystal form D.
Fig. 5 is a differential scanning calorimetry thermogram of said form D, as seen in fig. 5: said form D having an endothermic peak at 235 ℃; fig. 6 is a thermogravimetric analysis spectrum of the form D, as seen from fig. 6: the crystal form D is an anhydrous and solvent-free crystal form.
Example 2
Dissolving 10.0g of bacloxavir ester in a mixed solvent of 50mL of dichloromethane and 50mL of ethyl formate at room temperature, then dropwise adding 100mL of n-heptane, stirring and crystallizing for 1 hour, filtering, leaching a filter cake with n-heptane, and then vacuum drying at 60 ℃ for 8 hours to obtain 9.6g of solid, wherein an XRPD spectrum of the solid is basically consistent with that of figure 4, a differential scanning calorimetry spectrum of the solid is basically consistent with that of figure 5, and a thermogravimetric analysis spectrum of the solid is basically consistent with that of figure 6, and the solid is the crystal form D disclosed in the application.
Example 3
Adding 10.0g of baclovir ester, 40mL of dichloromethane and 50mL of methyl formate into a reaction bottle, heating to 35 ℃ for clearing, then dropwise adding 100mL of n-heptane, stirring for crystallization for 1 hour, then cooling to about 20 ℃, stirring and filtering, leaching a filter cake with n-heptane, and then vacuum drying at 80 ℃ for 6 hours to obtain 9.5g of solid, wherein an XRPD spectrum of the solid is basically consistent with that of figure 4, a differential scanning calorimetry spectrum of the solid is basically consistent with that of figure 5, and a thermogravimetric analysis spectrum of the solid is basically consistent with that of figure 6, and the solid is the crystal form D.
Example 4: stability test
According to the guiding principle of pharmaceutical preparation stability test, influence factor experiments are carried out on the crystal form D (prepared in examples 1-3) and the known crystal form I (prepared in example 10 of patent WO2018030463, wherein an XRPD spectrum of the crystal form D is shown in figure 7 and is basically consistent with that of figure 3 of WO 2018030463), the influence factor experiments comprise a high-temperature test, a high-humidity test and a strong-light irradiation test, and the stability conditions influencing the crystal form are examined:
high-temperature test: taking appropriate amount of the crystal form D and the crystal form I respectively, flatly placing the samples in a weighing bottle, placing the samples in a constant temperature and humidity box with the temperature of 70 ℃ and RH 75% for 10 days, taking about 100mg of the samples, and testing the crystal form condition of the samples by powder X-ray powder diffraction (XRPD), wherein the results are shown in Table 1 and figure 8;
high humidity test: taking appropriate amount of the crystal form D and the crystal form I respectively, flatly placing the samples in a weighing bottle, placing the samples in a constant temperature and humidity box with the temperature of 25 ℃ and RH of 92.5% for 10 days, taking about 100mg of the samples, and testing the crystal form condition of the samples by powder X-ray powder diffraction (XRPD), wherein the results are shown in Table 1 and figure 8;
and (3) illumination test: appropriate amounts of the samples of the crystal form D and the crystal form I are respectively taken, the samples are flatly paved into weighing bottles, the samples are placed for 10 days under the conditions of a constant temperature and humidity box (25 ℃, RH 60% +/-5%) with visible light 4500Lux +/-500 Lux (VIS) and ultraviolet light 1.7W X h/m2(UV), about 100mg of the samples are taken, and the crystal forms of the samples are tested by powder X-ray powder diffraction (XRPD), and the results are shown in Table 1 and figure 8.
TABLE 1 stability test results
| Sample crystal form | Crystal form D | Crystal form I |
| High temperature (70 ℃, |
Is still in crystal form D | Remains in crystal form I |
| High humidity (25 deg.C, RH 92.5%, 10 days) | Is still in crystal form D | Is still in crystal form I |
| Illumination (10 days) | Is still in crystal form D | Is still in crystal form I |
As can be seen from the combination of table 1 and fig. 8, form D described herein has the same stability as form I.
Example 5: solubility test
The following solutions were prepared with reference to the supplement of the Japanese pharmacopoeia:
ph1.2 solution: taking 2.0g of sodium chloride, adding a proper amount of water to dissolve, adding 7mL of hydrochloric acid, adding water to dilute to 1000mL, and uniformly mixing to obtain the sodium chloride;
ph4.0 solution: mixing 0.05mol/L acetic acid solution and 0.05mol/L sodium acetate solution according to the proportion of 16.4:3.6 to obtain the product;
ph6.8 phosphate buffer: 1.7g of monopotassium phosphate and 1.775g of anhydrous disodium hydrogen phosphate are taken, dissolved in water and added to a constant volume of 1000mL, and the potassium phosphate-disodium hydrogen phosphate-disodium salt is obtained.
And respectively taking a proper amount of crystal form D and a proper amount of crystal form I samples, dissolving the crystal forms respectively with a pH1.2 solution, a pH4.0 solution and a pH6.8 phosphate buffer solution to prepare saturated solutions, centrifuging, carrying out HPLC content analysis on supernate, and calculating the corresponding solubility. The specific experimental results are shown in table 2.
Table 2 solubility test results
| Sample crystal form | Crystal form D | Crystal form I |
| PH1.2，37℃ | 22.68μg/mL | 20.6μg/mL |
| PH4.0，37℃ | 24.98μg/mL | 19.3μg/mL |
| PH6.8，37℃ | 23.54μg/mL | 18.9μg/mL |
It can be seen from the results shown in table 2: the crystal form D of the baroxavir disoproxil has solubility superior to that of the existing crystal form I in the pH environment simulating gastrointestinal fluids, and is very favorable for absorption and utilization of oral preparations.
In addition, proper amounts of crystal form D and crystal form I samples are respectively taken, and the crystal habit of the samples is observed under a microscope at a magnification of 100 times:
fig. 9 is a crystal habit photograph of the crystal form D described in the present application, and it can be seen from fig. 9: the crystal habit of the crystal form D is a slender needle-shaped crystal, the particle dispersibility is good, and the crystal form D has good fluidity and compressibility and is very suitable for being used as a raw material of a tablet;
fig. 10 is a crystal habit photograph of the known crystal form I, which can be seen from fig. 10: the crystal habit of the crystal form I is flaky, and flaky crystals are easy to wrap a solvent and agglomerate in the process of drying materials, so that the dried materials are hard, the solvent residue is easy to exceed the standard, the solvent limit can be reached by long time of drying, and the excessive drying time is easy to cause the standard exceeding of degraded impurities; in addition, after the materials are agglomerated, the flowability of the product is poor, the requirement on granularity needs to be met through physical crushing, and the production and preparation of tablets are disturbed, so that the material is not an ideal raw material for preparing the tablets.
Finally, it should be pointed out here that: the above is only a part of the preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention, and the insubstantial modifications and adaptations of the present invention by those skilled in the art based on the above description are intended to be covered by the present invention.
Claims (10)
1. A crystalline form D of baroxavir disoproxil, being an anhydrous solvate-free crystalline form of baroxavir disoproxil, characterized in that: under X-ray powder diffraction, the powder has characteristic diffraction peaks at diffraction angles 2 theta of 4.5 degrees, 8.8 degrees, 10.8 degrees, 13.2 degrees, 14.3 degrees, 14.8 degrees and 16.2 degrees, and the test error is +/-0.2 degrees.
2. Crystalline barloxavirate form D according to claim 1 characterized by: under X-ray powder diffraction, the powder diffraction has characteristic diffraction peaks at diffraction angles 2 theta of 4.5 degrees, 8.8 degrees, 9.8 degrees, 10.8 degrees, 11.7 degrees, 13.2 degrees, 14.3 degrees, 14.8 degrees, 15.8 degrees, 16.2 degrees, 16.5 degrees, 17.3 degrees, 17.5 degrees, 17.8 degrees, 18.8 degrees, 20.2 degrees, 21.6 degrees, 21.9 degrees, 22.3 degrees, 24.2 degrees, 24.4 degrees, 26.5 degrees, 28.0 degrees, 28.3 degrees, 29.7 degrees and 31.5 degrees, and the test error is +/-0.2 degrees.
3. Crystalline barloxavirate form D according to claim 1, characterized by: the DSC spectrogram of the crystal form D of the baroxavir disoproxil has an endothermic peak at 235 ℃.
4. A process for preparing crystalline barloxavirate form D of claim 1 comprising the steps of:
a) dissolving a baroxavir base material in a mixed solvent formed by dichloromethane and an ester solvent according to a volume ratio of 1.0 (0.5-2.5) at a dissolving temperature of 20-50 ℃ to obtain a clear solution;
b) then, dropwise adding n-heptane into the system, and stirring to crystallize;
c) filtering and collecting precipitated crystals;
d) and c) drying the crystal obtained in the step c) for 6-15 hours at 50-100 ℃ in vacuum to obtain the crystal form D of the baroxavir disoproxil.
5. The method of claim 4, wherein: in the step a), the dissolving temperature is 20-40 ℃.
6. The method of claim 4, wherein: in step a), the form of the baroxavir disoproxil raw material is amorphous or any known crystal form or a mixture thereof.
7. The method of claim 4, wherein: in the step a), the mass-to-volume ratio of the baroxavir ester raw material to the mixed solvent is 1 g (8-15) ml.
8. The method of claim 4, wherein: in the step a), the volume ratio of the dichloromethane to the ester solvent in the mixed solvent is 1.0 (0.8-1.2).
9. The method of claim 4, wherein: in the step a), the ester solvent is at least one selected from methyl benzoate, ethyl benzoate, methyl formate, ethyl formate, isopropyl formate, butyl formate and butyl acetate.
10. The method of claim 4, wherein: in the step b), the ratio of the volume of n-heptane used to the volume of the mixed solvent used in the step a) is (1-1.2): 1.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011262612.XA CN114478575A (en) | 2020-11-12 | 2020-11-12 | Barosavirenz crystal form D and preparation method thereof |
| PCT/CN2021/125344 WO2022100395A1 (en) | 2020-11-12 | 2021-10-21 | Baloxavir marboxil crystal form d and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011262612.XA CN114478575A (en) | 2020-11-12 | 2020-11-12 | Barosavirenz crystal form D and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114478575A true CN114478575A (en) | 2022-05-13 |
Family
ID=81490743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011262612.XA Pending CN114478575A (en) | 2020-11-12 | 2020-11-12 | Barosavirenz crystal form D and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114478575A (en) |
| WO (1) | WO2022100395A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3428170T3 (en) * | 2015-04-28 | 2021-05-31 | Shionogi & Co., Ltd | Anti-influenza polycyclic pyridone derivative and prodrug thereof |
| WO2020058745A1 (en) * | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
| CN109504721B (en) * | 2018-12-26 | 2021-07-09 | 杭州科巢生物科技有限公司 | Synthetic method of anti-influenza medicine |
| WO2020181025A1 (en) * | 2019-03-05 | 2020-09-10 | Assia Chemical Industries Ltd | Solid state forms of baloxavir marboxil |
| CN114258395A (en) * | 2019-09-27 | 2022-03-29 | 广东东阳光药业有限公司 | Crystal form of ester compound and preparation method thereof |
| CN111233891B (en) * | 2020-03-04 | 2021-05-04 | 江苏柯菲平医药股份有限公司 | Fused ring pyridone derivative and preparation method and application thereof |
| CN111647005A (en) * | 2020-06-15 | 2020-09-11 | 安徽皓元药业有限公司 | Barosavir new crystal form and preparation method thereof |
| CN111875619B (en) * | 2020-07-30 | 2021-06-25 | 深圳市新阳唯康科技有限公司 | Crystal form of Barosavir ester and preparation method thereof |
-
2020
- 2020-11-12 CN CN202011262612.XA patent/CN114478575A/en active Pending
-
2021
- 2021-10-21 WO PCT/CN2021/125344 patent/WO2022100395A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022100395A1 (en) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3470400A1 (en) | Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor | |
| US20080086005A1 (en) | Novel crystalline forms of aripiprazole | |
| WO2011095059A1 (en) | Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof | |
| JPS6245576A (en) | Production of stable derivative of tracemide and diuretic containing stable torasemide | |
| JP3726291B2 (en) | Benzoxazine compound having stable crystal structure and process for producing the same | |
| WO2012022240A1 (en) | Novel crystal of erlotinib base and the preparation method thereof | |
| CN112047893B (en) | Gefitinib and salicylic acid co-crystal | |
| CN114478575A (en) | Barosavirenz crystal form D and preparation method thereof | |
| EP1295870B1 (en) | Suplatast tosilate crystals | |
| AU2016236659B9 (en) | AHU377 crystal form, preparation method and use thereof | |
| CN113336741B (en) | Rabeprazole sodium anhydride crystal form and preparation method thereof | |
| CN109438370B (en) | Methylpyrazine derivative anhydrous crystal form | |
| WO2021129651A1 (en) | 2-[4-[(e)-(2-ketocyclohexenyl)methyl]phenyl]propionic acid crystal form and preparation method therefor | |
| CN108264465B (en) | Dapoxetine hydrochloride monohydrate, preparation method and application thereof | |
| CN110372635B (en) | Preparation method of vortioxetine hydrobromide alpha crystal form | |
| CN106957312B (en) | Raltitrexed hydrate crystal forms and preparation method thereof | |
| CN117466914A (en) | Novel crystal form of balo Sha Weizhi and method for purifying products by using novel crystal form | |
| CN105461618B (en) | Methanesulfonic acid Lome Tapai novel crystal forms and preparation method thereof | |
| AU2007200816B2 (en) | A new crystalline and stable form of andolast | |
| CN112225732B (en) | Crystal form of pirone hydrochloride hydrate and preparation method thereof | |
| WO2013013594A1 (en) | Amorphous substance of 17α-acetoxy-11β-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and preparation method thereof | |
| CN111094313B (en) | Crystalline form of idarubicin hydrochloride monohydrate | |
| CN115073384B (en) | Acipimox crystal form and preparation method thereof | |
| CN107266518B (en) | Mometasone furoate crystal form and preparation method thereof | |
| CN103819469A (en) | Crystal form of dasatinib and preparation method for crystal form of dasatinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |